About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Ovarian Cancer Clinical Trials in Denver | 119 Studies

Clinical Trials Ovarian CancerDenver

Ovarian Cancer Clinical Trials in Denver

Find 119 clinical trials for ovarian cancer near Denver, Colorado. Connect with research centers in your area.

All Ovarian Cancer trials nationwide All trials in Denver

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 1-20 of 119 trials

RecruitingA Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid TumorsThis study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.NCT07182149·Denver, Colorado and 17 others CompletedA Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)The goal of this clinical trial is to test the safety and efficacy of KVA12123 alone or combined with pembrolizumab in patients with advanced solid tumors.NCT05708950·Santa Monica, California and 6 others

Ovarian Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

CompletedBevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity CancerThis randomized phase II trial studies how well bevacizumab with or without fosbretabulin tromethamine works in treating patients with ovarian epithelial, fallopian tube, or…NCT01305213·Phoenix, Arizona and 50 others

RecruitingSafety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple MyelomaStudy QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or…NCT06582017·Los Angeles, California and 9 others

TerminatedA Study With NKT3447 for Adults With Advanced/Metastatic Solid TumorsThe goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, and pharmacokinetics (PK) to determine the maximum tolerated dose (MTD) and/or…NCT06264921·San Francisco, California and 7 others

Active not recruitingComparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic AgentsThis phase II trial studies the possible benefits of treatment with different combinations of the drugs durvalumab, olaparib and cediranib vs. the usual treatment in patients with…NCT04739800·Anchorage, Alaska and 390 others

CompletedOxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based ChemotherapyRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.NCT00005836·Birmingham, Alabama and 73 others

RecruitingJAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C MutationThis study is to evaluate the efficacy and safety of JAB-30355 in adult participants with advanced solid tumors harboring TP53 Y220C mutation.NCT06386146·Denver, Colorado and 14 others

Active not recruitingStudy BT8009-100 in Subjects With Nectin-4 Expressing Advanced MalignanciesThis study is a Phase I/II, multicenter, first-in-human, open-label dose-escalation study of BT8009 given as a single agent and in combination with pembrolizumab in participants…NCT04561362·Denver, Colorado and 23 others

RecruitingA Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid TumorsThis phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of CUSP06 in patients with platinum-refractory/resistant ovarian cancer and other…NCT06234423·Denver, Colorado and 14 others

UnknownPaclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity CancerThis randomized phase III trial studies paclitaxel and carboplatin see how well they work compared with paclitaxel and ifosfamide in treating patients with fallopian tube, or…NCT00954174·Birmingham, Alabama and 537 others

TerminatedEfficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer PatientsThe purpose of this study is to evaluate the benefit of vaccination with Abagovomab, an experimental immunotherapy in ovarian cancer patients.NCT00418574·Los Angeles, California and 149 others

TerminatedA Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerThe MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer) is a Phase 3 study during which patients with recurrent or persistent low-grade serous (LGS) carcinomas of the…NCT01849874·Phoenix, Arizona and 225 others

TerminatedEvaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid TumorsThe objective of this study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of BL-M17D1 in patients with HER2-Expressing or HER2-Mutant Advanced or Metastatic…NCT06714617·Denver, Colorado and 8 others

Active not recruitingNivolumab and Ipilimumab in Treating Patients With Rare TumorsThis phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors.NCT02834013·Birmingham, Alabama and 1006 others

TerminatedStudy of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene AmplificationsBBI-355 is an oral, potent, selective checkpoint kinase 1 (or CHK1) small molecule inhibitor in development as an ecDNA (extrachromosomal DNA) directed therapy (ecDTx).NCT05827614·Los Angeles, California and 15 others

CompletedA Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid TumorsThis is a first-in-human, open-label, dose escalation study to evaluate the safety and tolerability of pegilodecakin in participants with advanced solid tumors, dosed daily…NCT02009449·Los Angeles, California and 9 others

RecruitingTesting Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian CancerThis phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination…NCT06580314·Birmingham, Alabama and 694 others

CompletedS9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in RemissionRATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.NCT00003120·Mobile, Alabama and 92 others

RecruitingA Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9The main goal of this study is to evaluate the safety of BNT329 and to identify the best dose of BNT329.NCT07186842·Denver, Colorado and 16 others

Page 1 of 6Next

Other Conditions in Denver

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia